All In Biotech

Drug Trial Radar · NCT04796428

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

Intraclass Safety and Efficacy Comparison Among SGLT-2 Inhibitors in Elderly Patients With Type 2 Diabetes. A Pragmatic, Phase IV, Multicenter, Open-label, Randomised Controlled Trial.

Last checked: Nov 19, 2026Latest source record: Mar 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,167 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,167

Planned (sponsor's estimate)

Start

Jun 30, 2021

Primary completion

Dec 31, 2023

Study completion Dec 31, 2023

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Italian Society of Diabetology
First posted
Mar 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 70 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Three SGLT2i were commercially available in Italy at the time the trial was designed: canagliflozin, dapagliflozin, and empagliflozin. Preliminary evidence suggests that the higher dose canagliflozin (300 mg/day) might exert a stronger glucose-lowering effect than dapagliflozin or empagliflozin. The clinical relevance of this putative difference is however unknown. On the other side, the use of canagliflozin, but not empagliflozin and dapagliflozin, has been associated with an increased risk of some adverse events, namely bone fractures and lower limb amputations. Currently, the available information on the efficacy and safety of SGLT2i in elderly (70+ years) patients with type 2 diabetes are is very scant. Thus, a compelling need now exists of comparing efficacy and safety of the commercially available SGLT2i in a population of frail patients at high risk of cardiovascular and renal diseases.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • CanagliflozinDrug

    Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.

  • DapagliflozinDrug

    Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used. If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used.

  • EmpagliflozinDrug

    If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used. If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary ObjectiveTime frame: Up to 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.